Navigation Links
Amira Pharmaceuticals Announces Completion of Phase 1 Clinical Study for AM152, A Novel LPA1 Receptor Antagonist
Date:5/2/2011

SAN DIEGO, May 2, 2011 /PRNewswire/ -- Amira Pharmaceuticals, Inc. announced today initial positive data from a Phase 1 clinical study of AM152, the Company's oral selective antagonist of the LPA1 receptor.  Completion of this study positions Amira to initiate a Phase 2a study in patients suffering from systemic sclerosis, a systemic fibrotic disease, by early 2012.

"The Phase 1 clinical study in healthy volunteers demonstrated that AM152 is safe and well-tolerated at doses which are expected to provide a full range of receptor coverage in humans," said Isabelle DeArmond, Vice President, Clinical Development. "These results enable us to study AM152 at a wide range of doses in patients suffering from fibrotic diseases."

Bob Baltera, Chief Executive Officer, added, "Initiating a Phase 2a study in patients suffering from systemic sclerosis will be an important milestone for the team at Amira; we look forward to better understanding the potential therapeutic benefit of AM152."

AM152 is a novel LPA1 receptor antagonist developed by the scientists at Amira.  Preclinical data has demonstrated that antagonism of the LPA1 receptor inhibits fibrosis in several disease models.  Much of these data has been previously presented and published by Amira scientists and colleagues.  Amira Pharmaceuticals also recently announced that AM152 was granted Orphan Drug Status by the FDA for patients suffering from idiopathic pulmonary fibrosis (IPF).

About Amira

Founded in 2005 and headquartered in San Diego, Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory and fibrotic diseases.  Amira combines the rigor of a big pharmaceutical company with the ingenuity and energy of a small company, creating an environment for efficient development of novel compounds and effective pre-clinical and clinical program decisions.
'/>"/>

SOURCE Amira Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Amira Pharmaceuticals Receives Orphan Drug Status for a Novel LPA1 Antagonist, AM152, for the Treatment of Idiopathic Pulmonary Fibrosis
2. Amira Pharmaceuticals Announces the Nomination of an Orally Available Pre-Clinical Candidate in a New LPA-Related Program, an Autotaxin Inhibitor
3. Amira Pharmaceuticals Announces Initiation of Phase I Clinical Trial for AM152, A Novel LPA1 Antagonist
4. Amira Pharmaceuticals Announces IND Submission for Novel LPA1 Antagonist, AM152, for Potential Use in Fibrotic Diseases
5. Amira Pharmaceuticals Named One of Most Promising Biotech Companies by FierceBiotechs Annual Fierce 15
6. Visage Imaging Releases Amira 5.3
7. Amira Announces AM103 and AM803 Patent Grant in the United Kingdom
8. Amira Announces Second DP2 Antagonist Patent Grant in the United Kingdom
9. Anti-Fibrotic Data from Amira Pharmaceuticals LPA1 Receptor Antagonist Program Published in the British Journal of Pharmacology
10. Amira Pharmaceuticals Announces Efficacy of LPA1 Antagonist in a Preclinical Model of Scleroderma
11. Amira Pharmaceuticals Announces Initial Positive Phase 1 Clinical Data for AM461, A Back-Up to Amiras Lead DP2 Antagonist, AM211
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... SANTA BARBARA, Calif. , Dec. 23, 2014 ... the Junior Doctors, Association of Sierra Leone ... Sierra Leone for the treatment of local ... While a new dedicated Ebola care center was ... Ebola virus, the facility is not available for local Sierra ...
(Date:12/22/2014)... , Dec. 22, 2014  CytoSorbents Corporation (OTCQB:CTSOD), ... CytoSorb® blood purification technology to help fight deadly ... 28 countries worldwide, today announced the appointment of ... FACS, as its Senior Vice President of Clinical ... Dr. Di Russo is an accomplished ...
(Date:12/22/2014)... and Markets ( http://www.researchandmarkets.com/research/h3xm6q/us ) has announced ... Market" report to their offering. ... focuses on the developments in the self-monitoring blood glucose ... Reimbursement analysis and the effects of competitive bidding have ... SMBG meters have been performed, based on the various ...
Breaking Medicine Technology:First Ebola Treatment Unit for Local Health Workers Arrives in Sierra Leone 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5US Self-monitoring Blood Glucose Market 2
... Sheets: SIMH)  In a shrewd execution of its business ... with Keith Houlihan, Co-founder and President of Sanomedics ... signing of a letter of intent to acquire a ... platform in sleep apnea treatment services.  The targeted acquisition ...
... Dec. 12, 2011  Inovio Pharmaceuticals, Inc. (NYSE Amex: ... and infectious diseases, announced today that Dr. J. Joseph Kim, ... at the Oppenheimer 22nd Annual Healthcare Conference taking place December ... Inovio Presentation December 13 10:50 am ET ...
Cached Medicine Technology:Sanomedics Signs Letter of Intent to Acquire Large Sleep Disorder Service Based Operation 2Inovio Pharmaceuticals to Present at Oppenheimer Investor Conference 2Inovio Pharmaceuticals to Present at Oppenheimer Investor Conference 3
(Date:12/24/2014)... a famous bamboo flooring company offering bamboo flooring products ... its multiple layer bamboo panel board collection , and ... Bamboo panel is the product made from 100 percent ... features high quality selective bamboo and eco-friendly adhesives that ... consists of multiple layers of bamboo. , According to ...
(Date:12/24/2014)... -- The holidays can be a challenge for people who ... and drinks. "This is the season in which many ... Dr. David Dodick, chair of the American Migraine Foundation, said ... to think through food and beverage choices, to help reduce ... professor of neurology at the Mayo Clinic in Scottsdale, Ariz. ...
(Date:12/24/2014)... News) -- A new, injectable weight-loss drug has been ... The agency on Tuesday approved Saxenda (liraglutide) for adults ... and have at least one weight-related health condition, such ... cholesterol. Patients taking the drug, made by Novo ... regularly, the FDA noted. "Obesity is a public ...
(Date:12/24/2014)... WEDNESDAY, Dec. 24, 2014 (HealthDay News) -- Researchers say ... cells that develop into eggs and sperm. While ... this is the first time that these types of ... produced efficiently using human stem cells, according to the ... "The creation of primordial germ cells is one of ...
(Date:12/24/2014)... -- A lab technician with the U.S. Centers for ... the Ebola virus in an agency laboratory in Atlanta ... other lab workers are being checked for possible exposure, ... exposure occurred Monday when CDC scientists doing research on ... virus to another CDC lab in the same building, ...
Breaking Medicine News(10 mins):Health News:Bamboo Flooring Company Bambooindustry.com Introduces Its Multiple Layer Bamboo Panel Board Collection 2Health News:Expert Offers Tips for Preventing Holiday Migraines 2Health News:FDA Approves New Weight-Loss Drug 2Health News:FDA Approves New Weight-Loss Drug 3Health News:CDC Monitors Lab Worker for Possible Ebola Exposure 2
... Health Minister, Andy Kerr, praised the services of NHS ... remarkably, but added that the confidence on the Scotland's// ... ,The service dealing with out-of-hours health inquiries had come ... died due to crucial time delays in the service ...
... A special drive to check fever has been launched by ... epidemic being reported in the city in the last 5// ... staff will go house-to-house to give medicines.” ... has led to hundreds of people being admitted to the ...
... In spite of laws that require limiting of the amount ... to 'black lung' or pneumoconiosis, according to a report from// ... ,The Coal Workers' Health Surveillance Program has identified 30 miners ... 11 were diagnosed with advanced disease according to the report ...
... one-year anniversary of Hurricane Katrina, the American Academy of ... prepare// for potential natural and other disasters to minimize ... ,Children are especially vulnerable during and after disasters. The ... their children, so the children will know what to ...
... have met with unprecedented success. The project was successful in ... to 12. ,The three-year study found that kids ... of children. "Most people would think individual weight loss of ... shifting (the weight of) a couple thousand kids and that's ...
... in the US have claimed today that they have developed ... embryos.// ,The scientists had also expressed their opinion ... for the approval of stem cell research as the key ... ,Publishing the findings in today’s online issue of Nature, Dr. ...
Cached Medicine News:Health News:NHS 24 Helpline Service Improved Remarkably Says Health Minister 2Health News:US Miners Still Prey to Black lung Disease 2Health News:AAP Urges Families To Create Emergency Disaster Plans 2Health News:AAP Urges Families To Create Emergency Disaster Plans 3
... Cutter has application in multiple open or ... resection, and/or creation of anastomoses and can ... buttressing materials such as bovine pericardium., ... a total of eight firings. Different cartridges ...
... in Open Procedures with Compact Endoscopic ... Compact-Flex45 No-Knife Articulating Linear Staplers is ... line for open surgical procedures. It ... blue cartridge, a thick-tissue green cartridge, ...
... ENDO CLIP MultApplier reusable clip applier is designed ... loading unit, each of which contains eight (8) ... shaft of the instrument is approximately 12.8" (32.5 ... and use through an appropriately sized Auto Suture ...
ENDO CLIP II ML, 10 mm Pistol Grip Single Use Clip Applier with Medium - Large Super Interlock Titanium Clips...
Medicine Products: